![]() |
市场调查报告书
商品编码
1351137
2030 年註射包装市场预测 - 按产品类型、材料类型、包装类型和地区分類的全球分析Parenteral Packaging Market Forecasts to 2030 - Global Analysis By Product Type (Vials, Pre-filled Syringes, Cartridges, Bags and Other Product Types), Material Type (Glass, Plastic and Other Material Types), Packaging Type and By Geography |
根据 Stratistics MRC 的数据,2023 年全球注射包装市场规模为 122.4 亿美元,预计到 2030 年将达到 190.3 亿美元,预测期内年复合成长率为 6.5%。
肠胃外包装是一种用于药品和保健产品的解决方案,可让药物或其他液体在储存期间直至给药之前保持其效力或治疗效果。高死亡率以及对 COVID-19 疫苗需求的增加,推动了对快速交付药物和药物的需求,同时又不丧失对各种慢性疾病的疗效。因此,对疫苗和药物的需求增加,保护它们免受污染的需求也增加。
根据USP(美国药典),注射用包装容器使用的玻璃有两种。 I 型玻璃是硼硅酸盐玻璃,用于中性配方。 Ⅱ型是钠钙玻璃,用于包装酸性、碱性和中性肠胃外製剂。
随着世界主要经济体人均卫生服务消费量的增加,人们认为全球注射包装市场的扩大。基于抗体的免疫是一项重要的福利介入措施,可显着改善大众的健康。家长的担忧与疫苗接种密切相关。例如,公共当局定期提出美国国家疫苗计划(NVP)和2011-2020年全球疫苗行动计划(GVAP)等免疫计划,以根除小儿麻痹和肝炎等疾病。进一步提振注射剂捆绑市场。
研究、开发和实施先进封装技术所需的大量初始投资是该行业面临的最大挑战之一。这包括设计和製造专用包装设备和材料的成本。此外,如果小型製药公司和新兴企业无法为这些投资分配资金,它们在市场上成功竞争的能力可能会受到限制。
注射包装公司有机会与製药商合作,开发尖端的药物传输系统,例如可穿戴注射器、自动注射器和带有感测器的智慧包装。此外,这些技术进步提高了患者的舒适度、依从性和依从性,并为创意包装概念开闢了新市场。
注射剂包装市场竞争激烈,许多企业争夺市场占有率。由于製造商与製药公司争夺合约,这种激烈的竞争往往会带来价格压力。因此,企业可能会发现很难在保持高标准的同时将资源分配给研发和创新,这可能会导致报酬率下降。
注射剂包装市场在许多方面都受到了 COVID-19 大流行的严重影响。随着製药公司争先恐后地开发和分销 COVID-19 疫苗和治疗方法,需求最初有所增加,尤其是对疫苗和基本药物的包装用品和解决方案的需求。此外,需求的增加给供应链带来了压力,导致一些包装零件出现短期短缺和价格变化。疫情也造成物流和製造中断,导致生产和分销放缓。
预计预充式註射器细分市场将在整个预测期内占据最大的市场份额。製药公司更喜欢预充式註射器,因为它们易于使用且给药准确,使其成为疫苗、胰岛素和生物製剂等各种注射药物的良好选择。此外,这些注射器已经含有单一剂量的药物,减少了污染或给药错误的机会。此外,它适用于快速发展的生物技术领域,因此经常用于新生物疗法的给药。
塑胶产业预计将呈现良好的成长动能。聚丙烯和环烯烃聚合物 (COP) 等塑胶材料因其柔韧性、重量轻和比玻璃更低的製造成本而普及。塑胶瓶和容器经常用于注射剂包装,特别是口服液和一些注射。此外,预充式塑胶注射器和输液袋等塑胶包装技术的发展是创造性和复杂的塑胶包装解决方案的例子。
预计北美在预测期内将占据最大的市场份额。该地区成熟的製药和生物技术部门是其占据市场主导地位的主要原因,从而推动了对复杂且合规的包装解决方案的需求。此外,北美对药物安全、以患者为中心的包装和医疗保健提供系统创新的关注巩固了其在全球注射剂包装市场的领先地位。
预计欧洲将在预期期间录得强劲成长。欧洲强劲的製药和生物技术行业以及严格的法规环境推动了一流注射剂包装解决方案的持续创新和采用。此外,欧洲市场的特点是高度重视环境永续性,鼓励创造和采用环保包装产品和程序。对肠胃外药物(包括先进包装形式)的需求不断增长也是由于欧洲高龄化和慢性病患病不断上升所致。
According to Stratistics MRC, the Global Parenteral Packaging Market is accounted for $12.24 billion in 2023 and is expected to reach $19.03 billion by 2030 growing at a CAGR of 6.5% during the forecast period. Parenteral packaging is a type of solution used in pharmaceuticals and healthcare products that enables the medication or other fluid to maintain its potency and therapeutic effectiveness throughout the shelf life or until the drug is administered. The high mortality rate has fueled the demand for quick delivery of medications and drugs without loss of potency because of various chronic diseases, along with the rising demand for COVID-19 vaccines. The result has been a rise in demand for vaccines and medications, as well as the requirement to safeguard drugs from contamination.
According to USP (United States Pharmacopeia) there are two types of glass used for parenteral packaging containers. Type I glass is a borosilicate glass and used for neutral preparation. Type II is soda lime glass and is used for packaging acidic alkaline and neutral parenteral preparations.
The expansion of the global market for parenteral packaging is taken into account with the rising per capita consumption of medical services in the world's major economies. Antibody-based vaccinations are a significant well-being intervention that significantly improves the health of the general populace. Parenterally administered interest is closely related to immunization. For instance, vaccination programs like the National Vaccine Plan (NVP) by the U.S. and the Global Vaccine Action Plan (GVAP) 2011-2020, which are presented by the public authority at regular intervals to eradicate diseases like polio and hepatitis, are relying on them to further fuel the parenteral bundling market.
The sizeable initial investment needed for research, development, and implementation of advanced packaging technologies is one of the industry's biggest challenges. Included in this are the expenses incurred in the design and production of specialized packaging equipment and materials. Moreover, the inability of smaller pharmaceutical firms and startups to allocate funds for these investments may limit their ability to successfully compete in the market.
Parenteral packaging businesses have opportunities to work with pharmaceutical manufacturers as a result of the development of cutting-edge drug delivery systems like wearable injectors, auto-injectors, and smart packaging with sensors. Furthermore, these advancements in technology increase patient comfort, adherence, and compliance, opening up new markets for creative packaging ideas.
Intense competition is present in the parenteral packaging market, where many businesses are vying for market share. Price pressure is frequently a result of this fierce competition as manufacturers compete for contracts with pharmaceutical firms. As a result, companies may find it difficult to allocate resources for R&D and innovation while maintaining high standards, and as a result, profit margins may decrease.
The parenteral packaging market was significantly impacted by the COVID-19 pandemic in numerous ways. As pharmaceutical companies raced to develop and distribute COVID-19 vaccines and treatments, it initially resulted in increased demand for packaging supplies and solutions, particularly for vaccines and necessary medications. Moreover, this increase in demand put pressure on the supply chain, leading to brief shortages and changes in price for some packaging parts. The pandemic also caused logistical and manufacturing disruptions, which delayed production and distribution.
The pre-filled syringes segment is predicted to hold the largest market share throughout the forecast period. Pharmaceutical companies prefer pre-filled syringes because of how easy they are to use and how precisely they deliver dosages, which makes them a good option for a variety of injectable medicines like vaccines, insulin, and biologics. Moreover, these syringes already contain one dose of the medication, lowering the possibility of contamination and dosage mistakes. Additionally, they are also frequently used in the administration of novel biologic therapies because they are well suited for use in the rapidly developing field of biotechnology.
The plastic segment is estimated to witness lucrative growth. Due to their adaptability, light weight, and lower production costs compared to glass, plastic materials, such as polypropylene and cyclic olefin polymers (COP), have become more popular. Parenteral packaging frequently uses plastic vials and containers, particularly for oral liquids and some injectable drug formulations. Additionally, developments in plastic packaging technology, like pre-filled plastic syringes and infusion bags, are examples of creative and sophisticated plastic packaging solutions.
North America is expected to witness the largest market share during the forecast period. The established pharmaceutical and biotechnology sectors in this area are largely responsible for the dominance of this market, which in turn drives demand for sophisticated and compliant packaging solutions. Additionally, its position as the top region in the global parenteral packaging market is cemented by North America's emphasis on drug safety, patient-centric packaging, and innovations in healthcare delivery systems.
Over the anticipated period, Europe is expected to register significant growth. The robust pharmaceutical and biotechnology industries in Europe, as well as its strict regulatory environment, encourage ongoing innovation and the adoption of top-notch parenteral packaging solutions. Moreover, the European market is distinguished by a strong focus on environmental sustainability, which has prompted the creation and adoption of eco-friendly packaging products and procedures. A growing demand for parenteral medications, including those in advanced packaging formats, has also been caused by Europe's aging population and an increase in the prevalence of chronic diseases.
Some of the key players in Parenteral Packaging market include: Nipro Corporation, Catalent, Inc, Sio2 Materials Science, Schott AG, Gerresheimer AG , Baxter International Inc., Dickinson and Company, Stevanato Group S.p.A., Corning Inc., UDG Healthcare plc, Becton, West Pharmaceutical Services, Inc. , UFP Technologies, Inc. and Terumo Corporation.
In June 30, 2021, SCHOTT AG announces the inauguration of its new tube factory in Jinyun, China. The new facility will help increase production for a pharmaceutical glass tubing company used to store and package life-saving medicines.
In May 19, 2020, Sharp, a subsidiary of UDG Healthcare plc, announced that it has acquired a 160,000-square-foot pharmaceutical packaging facility from Quality Packaging Specialists International, LLC, located in Macunji, Pennsylvania, USA.